Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as...
Saved in:
Main Authors: | HoUng Kim (Author), Rieke Alten (Author), Fraser Cummings (Author), Silvio Danese (Author), Geert D'Haens (Author), Paul Emery (Author), Subrata Ghosh (Author), Cyrielle Gilletta de Saint Joseph (Author), JongHyuk Lee (Author), James O. Lindsay (Author), Elena Nikiphorou (Author), Ben Parker (Author), Stefan Schreiber (Author), Steven Simoens (Author), Rene Westhovens (Author), Ji Hoon Jeong (Author), Laurent Peyrin-Biroulet (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ulcerative Colitis: Shifting Sands
by: Geert R. A. M. D'Haens, et al.
Published: (2019) -
Protein PEGylation for the design of biobetters: from reaction to purification processes
by: João Henrique Picado Madalena Santos, et al.
Published: (2018) -
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
by: Napolitano M, et al.
Published: (2022) -
Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
by: Mary Kaye Willian, et al.
Published: (2018) -
Biosimilar medicines and cost-effectiveness
by: Steven Simoens
Published: (2011)